Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Gains from Sales and Divestitures (2021 - 2026)

Axsome Therapeutics' Gains from Sales and Divestitures history spans 6 years, with the latest figure at $286136.0 for Q1 2026.

  • On a quarterly basis, Gains from Sales and Divestitures rose 17.13% to $286136.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $286136.0, a 17.13% increase, with the full-year FY2025 number at $321470.0, up 20.05% from a year prior.
  • Gains from Sales and Divestitures hit $286136.0 in Q1 2026 for Axsome Therapeutics, down from $321470.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for AXSM hit a ceiling of $321470.0 in Q4 2025 and a floor of $61581.0 in Q1 2022.
  • Historically, Gains from Sales and Divestitures has averaged $196227.4 across 5 years, with a median of $210490.0 in 2024.
  • Biggest five-year swings in Gains from Sales and Divestitures: surged 710.15% in 2022 and later increased 16.06% in 2025.
  • Tracing AXSM's Gains from Sales and Divestitures over 5 years: stood at $81639.0 in 2022, then skyrocketed by 138.15% to $194425.0 in 2023, then surged by 37.73% to $267779.0 in 2024, then increased by 20.05% to $321470.0 in 2025, then decreased by 10.99% to $286136.0 in 2026.
  • Business Quant data shows Gains from Sales and Divestitures for AXSM at $286136.0 in Q1 2026, $321470.0 in Q4 2025, and $295835.0 in Q3 2025.